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Abstract: Tofacitinib (TFB), a Janus kinase inhibitor, has shown excellent success off-label in treating
various dermatological diseases, especially alopecia areata (AA). However, TFB’s safe and targeted
delivery into hair follicles (HFs) is highly desirable due to its systemic adverse effects. Nanoparticles
(NPs) can enhance targeted follicular drug delivery and minimize interfollicular permeation and
thereby reduce systemic drug exposure. In this study, we report a facile method to assemble the
stable and uniform 240 nm TFB loaded squalenyl derivative (SqD) nanoparticles (TFB SqD NPs) in
aqueous solution, which allowed an excellent loading capacity (LC) of 20%. The SqD NPs showed an
enhanced TFB delivery into HFs compared to the aqueous formulations of plain drug in an ex vivo pig
ear model. Furthermore, the therapeutic efficacy of the TFB SqD NPs was studied in a mouse model
of allergic dermatitis by ear swelling reduction and compared to TFB dissolved in a non-aqueous
mixture of acetone and DMSO (7:1 v/v). Whereas such formulation would not be acceptable for use in
the clinic, the TFB SqD NPs dispersed in water illustrated a better reduction in inflammatory effects
than plain TFB’s aqueous formulation, implying both encouraging good in vivo efficacy and safety.
These findings support the potential of TFB SqD NPs for developing a long-term topical therapy
of AA.
Keywords: targeted drug delivery; hair follicle; in vivo allergic dermatitis mouse model; follicular delivery;
interfollicular delivery; nanoparticles; squalene
1. Introduction
Alopecia areata (AA) is one of the major non-scarring hair loss disorders with a lifetime incidence
of 2% [1–3]. AA is a complex disorder that involves breakdown of the immune privilege of anagen
hair follicles (HFs), leads to an attack of the immune system, and causes reversible hair loss with a
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preserved HF [1,4]. Although AA is a non-life-threatening disease, it still has a significant effect on
the patients’ quality of life [1,5]. The most common off-labeled treatment regimens for AA include
corticosteroids—applied intralesionally, topically or systemically, topical minoxidil, oral methotrexate,
or topical immunotherapy [6], while an approved medicine is not available due to the missing
therapeutic outcome prediction and the often-seen relapses [6].
A recently developed Janus kinase inhibitor (JAK-inhibitor) has demonstrated an impressive hair
regrowth in long-term alopecia universalis [7,8]. Namely, tofacitinib (TFB)—an FDA-approved
immunosuppressant against rheumatoid arthritis, psoriasis arthritis, and ulcerative colitis [9],
which inhibits JAK 1 and 3, has shown promising treatment progress on human and mice [10–13].
However, continuous treatment is necessary to gain a possible persistent success in hair regrowth [12,13].
Unfortunately, long-term systemic treatment with TFB can cause a broad and severe spectrum of
adverse effects due to the wide bioactive range of such JAKs [14]. JAKs are part of the intracellular
signaling pathway transducing cytokine signaling of both the types I and II cytokine receptor family.
Thus, JAK/STAT (signal transducers and activators of transcription) dependent cytokines have a broad
spectrum of action in humans, especially in hematopoiesis, inflammation induction, and immune
response control [14,15]. In 2019, TFB received an FDA-boxed warning due to an “increased risk of
blood clots and death with higher dose” [16]. Those facts emphasize the necessity of generating a safer
treatment profile for TFB, especially in non-life-threatening diseases like AA [5,17].
The TFB targeted HF delivery is considered as a good strategy to reduce the high systemic drug
levels and adverse effects. The topical application of the nanoparticulate drug delivery system
(NDDS) to the skin is able to (i) enhance drug solubility [18], (ii) deliver drugs targeted into
HFs [19,20], (iii) build up a drug depot [20,21], and (iv) release the drug in a controlled manner [22,23].
Consequently, nanoparticles (NPs) can deliver a higher amount of drug to HFs compared to plain
drug solution—meaning to maximize the follicular penetration while minimizing the interfollicular
permeation of drug molecules [22–24]. The primary mechanism of NPs deposition in HFs is the
postulated ratchet effect of cuticle cells in the hair shaft [20,25]. However, we have previously
demonstrated the deposition of NPs also in AA affected hairless human scalp HFs [26].
NDDS excipients composition can be chosen depending on their purpose, beside the conventional
approach of biodegradable polymers, for example, metal-based NDDS are used as antimicrobial
agents [27]. In addition, NDDS can release their cargo upon a triggering stimulus, e.g., by ultrasound
or infrared A radiation [28–30].
Taking advantage of an NP approach, we aimed to develop a NDDS for TFB targeted delivery to
AA affected HFs. Importantly, since a high dose of TFB—up to 5 or 10 mg orally twice daily—is clinically
required [9], a NDDS for TFB must have a high drug loading capacity (LC). Moreover, such a NDDS
should also be safe and easily prepared to meet future translational requirements [31]. The conventional
NDDS’s based on biodegradable polymers (e.g., poly (lactic-co-glycolic acid) (PLGA)) or nanostructured
lipid carriers (NLCs) offer good biocompatibility and are facile to produce. LC had, however,
been reported to be lower than 5% (w/w) [32,33], which was in good agreement with our attempts,
although previously a study claimed around 30% LC for TFB citrate salt loaded PLGA particles [34].
Squalene alone accounts for around 12% of the human sebum’s major components [35] and is a
precursor of the cholesterol biosynthesis throughout the human body [35,36]. Interestingly, squalene is
not further transformed in the sebaceous cells, which makes the skin the richest squalene containing
tissue in the human body [35,36]. Thus, squalene-based NPs for targeted follicular delivery would be
an excellent choice. Squalenoylation technology, which consists of linking a hydrophobic squalenyl
moiety to a more hydrophilic drug molecule, can significantly improve drug LC in self-assembled
squalenoylated NPs. This, moreover, could enhance the therapeutic efficacy of the drugs [37,38].
Unfortunately, the secondary amine in the pyrrole ring, which is the only availably reactive group in
TFB, is a relatively weak nucleophile for covalently coupling reactions. Possible attempts to synthesize
TFB prodrug are not facile [39]. Only the successful formation of a carbamate linkage was reported,
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leading to undesired long cleavage times for over three weeks [39]. Moreover, TFB is degraded in
harsh conditions making it less favorable in the chemically squalenyl modification [39–41].
Recently, we have reported an alternative to the squalenoylation approach, in which we used
amphiphilic squalenyl derivatives to formulate the surfactant-free self-assembled NPs allowing
significantly high drug LC in both hydrophilic and hydrophobic compartments [42–44].
Based on these studies we employed an anionic squalenyl derivative (SqD)—squalenyl hydrogen
sulfate—to produce the TFB loaded SqD NPs (TFB SqD NPs). This SqD is composed of a hydrophilic
hydrogen sulfate head-group covalently bonded to a hydrophobic moiety. We speculated that SqD NPs
could potentially allow the loading of TFB via charged interaction in the NPs shell and hydrophobic
interaction in the NPs core, hence giving a high LC of TFB. The TFB SqD NPs were moreover expected
to provide an enhanced TFB delivery in HFs and therapeutic effects.
We here first describe the preparation and characterization of TFB SqD NPs. In the subsequent
studies, we investigated the performance of TFB SqD NPs compared to formulations of the plain
drug and vehicle controls in some established ex vivo and in vivo models. The ex vivo pig ear model
was adopted from previously reported ones [45,46] and used to determine the TFB penetration
and permeation pathways—into either follicular or interfollicular skin areas. A well-established
in vivo allergic dermatitis mouse model was, in turn, used to evaluate the therapeutic efficacy of the
formulations in reducing an inflammatory response, which corresponds to a reduction in the ear
swelling upon being challenged with allergen [47]. Our ex vivo and in vivo findings reveal the TFB SqD
NPs as safe and efficient for targeted drug delivery to the hair follicles after topical administration.
2. Materials and Methods
2.1. Materials
TFB free base (TFB) and TFB citrate salt (TFB-C) were purchased from LC Laboratories,
Massachusetts, US. TFB-C was manufactured to enhance the water solubility of TFB and was in
this study used to prepare an aqueous drug reference solution. SqD was synthesized as described
previously [43,44]. Ammonium acetate (LC-MS grade) was purchased from Sigma-Aldrich, Munich,
Germany. Disodium hydrogen phosphate heptahydrate and sodium dihydrogen phosphate hydrate
were purchased from Carl Roth, Karlsruhe, Germany. Tetrahydrofuran (HPLC grade) (THF), ethanol,
absolute (HPLC grade; EtOH), formic acid (LC-MS grade), and dimethyl sulfoxide (DMSO) were
purchased from Fisher Scientific, Leicestershire, UK. Acetone (HPLC grade) was purchased from
Honeywell Riedel-deHäen, Fisher Scientific GmbH, Schwerte, Germany. Methanol (MeOH) was
obtained from VWR Chemicals, Darmstadt, Germany. A disposable biopsy punch with plunger with a
1 mm diameter was obtained from kai europe GmbH, Solingen, Germany. Millex®-LG syringe driven
filter units (PTFE, 0.20 µm) were purchased from Merck Millipore, Darmstadt, Germany. Faber Castell®
MULTIMARK permanent 152399, 0.4 mm in black was purchased from A.W. Faber-Castell Vertrieb
GmbH, Stein, Germany. Tesafilm kristallklar 33 m × 19 mm was a gift from tesa SE, Hamburg,
Germany. Dialysis bag SpetraPor®7, MWCO 10 kDa, consisting of regenerative cellulose was
purchased from Repligen Corporation, California, US. Milli-Q water purification system from Merck
Millipore (Darmstadt, Germany) was used to prepare purified water (water).
2.2. Animal Procedure and Ethics Statement
The animal experiment was approved on 27th of November in 2017 by state agency (LAGeSo Berlin,
approval number: G 0234/17). The experiments were conducted in female BALB/c (BALB/cAnNCrl)
aged 6–8 weeks. Mice were obtained from Charles River Laboratories (Sulzfeld, Germany).
Mice received a standard diet and water ad libitum. After arrival, mice were acclimatized to
their environment for 1 week.
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2.3. Preparation of TFB SqD NPs
TFB SqD NPs were prepared using free base TFB and anionic squalenyl derivative (SqD)—squalenyl
hydrogen sulphate (Figure 1)—whose detailed synthesis and characterization can be found in our
previous work [43,44]. The optimal TFB SqD NPs were produced by solvent evaporation technique.
In detail, TFB and SqD were separately solubilized in THF at a concentration of 2 mg/mL and 10 mg/mL,
respectively. An appropriate volume of each compound solution in THF was mixed to obtain a final
TFB:SqD (36.5:63.5 w/w) and a total 1 mg/mL concentration. Subsequent, phosphate buffer (10 mM) pH
6.75 (phos-buffer) was added reaching a THF:phos-buffer volume ratio of 1:0.9. The TFB SqD NPs were
formed upon slow evaporation of THF, and water was then partially removed (at 40 mbar, 40 ◦C, in a
Rotavapor R-300, Büchi, Essen, Germany) to reach a final TFB SqD NPs concentration of 5.5 mg/mL,
which contained an equivalent TFB concentration of 2 mg/mL. Drug-free SqD NPs were prepared
using the same procedure and served as controls.
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Figure 1. Schematic illustration of SqD and TF c emical str ctures, and the self-assembled drug-free
SqD NPs and TFB SqD NPs. Morphology of (a) drug-free SqD NPs and (b) TFB SqD NPs visualized by
cryo-TEM. Black scale bar equals 0.5 µm.
2.4. Quantification of Drug Loading Capacity and Encapsulation Efficiency
The quantity of drug in the TFB SqD NPs was determined using a direct method. In brief, 500 µL of
the TFB SqD NPs 5.5 mg/mL suspension was centrifuged at 24.400 g, 4 ◦C, for 4 h. Both supernatant and
NPs sediment were collected, of which the supernatant was further diluted in MeOH and ready for high
performance liquid chromatography (HPLC, Supplemental part 2) analysis, while the NPs sediment
was freeze dried (Lyo-Cube 4-8, Alpha 2-4 LSC, Christ, O terrode am Harz, Germany). Following the
total weight measurement of the dried NPs sediment, it was solubilized in a predetermined volume of
MeOH, then sonicated for 1 h in an ultrasound bath (Bandelin, Sonorex, Bandelin electronic GmbH
and Co. KG, Berlin, Germany). The subsequent solution was diluted in MeOH and analyzed by HPLC
(Supplemental part 2). The encapsulation efficiency (EE) and the drug loading capacity (LC) of TFB
SqD NPs were calculated as follows:
EE (%) = (TFB amount in NPs sediment/total TFB amount) × 100 (1)
LC (%) = (TFB amount in NPs sediment/total weight of NPs sediment) × 100 (2)
where in:
total TFB amount = TFB amount in the NPs sediment + TFB amount in the supernatant (3)
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At least three experiments were conducted and results are presented as mean ± standard
deviation (SD).
2.5. Size, Polydispersity Index, Zeta-Potential, and pH Value Determination
The hydrodynamic diameter (reported as intensity-based z-average) and the polydispersity index
(PdI) were determined by dynamic light scattering (DLS) using a Zetasizer (Zetasizer Nano ZSP,
ZEN5600, Malvern, UK, Software 7.02). The zeta-potential was determined by electrophoretic light
scattering (ELS), using the same equipment. The Zetasizer was equipped with a He-Ne Laser at a
wavelength of 633 nm, DLS was done at a backscattering angle of 173◦ and ELS at an angle of 13◦.
For the measurements, 20 µL of the final NP-suspension was diluted in 800 µL water. The pH of the
final NP-suspensions and aqueous drug solution of TFB-C in phos-buffer (2 mg TFB/mL) (aqTFB-C)
was determined by a pH meter (Mettler Toledo Seven Compact PHS 210 including pH electrode Mettler
Toledo InLab® Micro, Switzerland). To determine the colloidal storage stability of TFB SqD NPs and
drug-free SqD NPs at 4 ◦C, the measurements were repeated after 12 and 24 days. Three experiments
were conducted and measurements were done in triplicates. Results are reported as mean ± SD.
2.6. Morphology
The morphology of the TFB SqD NPs and of the drug-free SqD NPs were determined by cryogenic
transmission electron microscopy (cryo-TEM). Three microliters of each NP-suspension were plotted
for two seconds on a holey carbon grid (S147-4, Plano, Wetzlar, Germany) and subsequently plunged
into −165 ◦C liquid ethane. Under liquid nitrogen conditions they were transferred to a Gatan model
914 cryo-TEM sample holder (Pleasonton, CA, USA). The sample analysis was done at −170 ◦C under
low dose conditions, using a JEOL (Akishima, Tokio, Japan) JEM-2100 LaB6 TEM equipped with a
Gatan Orius SC1000 CCD camera to gain bright field images.
2.7. In Vitro Release Study
The in vitro release profile of TFB SqD NPs was determined at pH 5.0 (ammonium acetate buffer,
10 mM) and 32 ◦C to simulate skin conditions [48], over a 24 h period using a dialysis bag method.
In brief, following the equilibration of the dialysis membrane in the ammonium acetate buffer, 900 µL
of the final TFB SqD NPs suspension was loaded into a dialysis bag consisting of regenerative cellulose
(MWCO 10 kDa). Subsequently, the loaded dialysis bag was sunk in 30.0 mL ammonium acetate buffer,
and the whole system was shaken at 100 rpm, 32 ◦C. At predetermined time points (0.25, 0.5, 0.75, 1, 2,
4, 6, and 24 h), 500 µL of the release medium was withdrawn, and an equal volume of fresh buffer was
added. The samples were then analyzed by HPLC (Supplemental part 2). The maximum solubility of
TFB in the ammonium acetate buffer was determined at 115.6 ± 9.3 µg/mL prior to the experiment.
Three experiments were conducted and results are expressed as mean ± SD.
2.8. Ex Vivo and In Vivo Performance of TFB SqD NPs
We evaluated the HFs targeted transport and therapeutic efficacy of TFB SqD NPs in comparison
to plain drug solutions in an ex vivo pig ear model and an allergic dermatitis mouse model, respectively.
2.8.1. Targeted Follicular Transport of TFB in a Pig Ear Model
Excised hairy human skin cannot be used for follicular penetration studies of therapeutics, due to
the shrinkage of the follicular reservoir of around 90%. This effect can be precluded in the pig ear model,
where the skin remains on the cartilage [49–51]. Hence, in this study, we investigated the follicular and
interfollicular penetration and permeation of TFB (the terms penetration and permeation are defined
in the Supplemental part 4 and used according to Ref. [52]) in a pig ear model, which we optimized
from two previously described methods, namely the differential stripping method [45,53] and the
single HF harvesting method [46]. The differential stripping consists of two major steps—the surface
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cleaning by tape stripping to remove the formulation left on the skin surface, and the harvesting of the
follicular casts by cyanoacrylate biopsies, including the formulation deposited in HFs. Unfortunately,
the cyanoacrylate biopsies were not compatible and interfered with the TFB LC-MS quantification
method. Therefore, the harvesting of the HFs was done as previously described by Kalia and coworkers:
intact HFs were collected by 1 mm diameter punch biopsies (follicular skin). Accordingly, interfollicular
drug penetration was determined by HF-free 1 mm diameter punch biopsies (interfollicular skin) [46].
The investigated drug formulations and tested vehicle control groups are summarized in Table 1.
Table 1. Abbreviation, composition, formulation type, number of pig ears, and number of application
areas used for ex vivo pig ear study on topical penetration and permeation pathways.
Group Abbreviation Components FormulationType No. Ear No. Area
Treatment
(TFB 2 mg/mL)
TFB SqD NPs TFB 1, SqD 2, phos-buffer 3 suspension 4 7
aqTFB-C TFB-C 4, phos-buffer 3 solution 2 4
TFB-EtOH TFB 1, EtOH 5:H2O (50:50 v/v) solution 3 6
TFB-acet:DMSO TFB 1, acetone:DMSO 6 (7:1 v/v) solution 3 6
vehicle control
phos-buffer phos-buffer 3 solution 4 4
EtOH:H2O EtOH 5:H2O (50:50 v/v) solution 3 3
acet:DMSO acetone:DMSO 6 (7:1 v/v) solution 3 3
1 tofacitinib free base, 2 anionic squalenyl derivative, 3 phosphate buffer, 4 tofacitinib citrate, 5 ethanol,
6 dimethyl sulfoxide.
The experiments on the pig ear model were as follows: the ears were collected from freshly
slaughtered pigs, cleaned with water, and carefully dried with paper tissues. The ears were stored
for a maximum of 7 days at 4 ◦C. Only ears with intact skin were used and the experiments were
conducted on the outer auricle of the ear. In an experiment, a pig ear was firstly fixed on an aluminum
foil covered wooden board. Subsequently, the hair shafts were shortened to 1 mm with an electrical
clipper, during which the skin barrier was surely maintained (Braun Bartschneider, BT3040, Procter and
Gamble Service GmbH, Schwalbach am Taunus, Germany). The areas for investigation with a surface
area of 1.767 cm2 were marked, and there were at least two areas for the treatment group and one
area for the vehicle control on each ear (Table 1). A 15 µL of the formulation—treatment or vehicle
control—was applied on each marked area, which was then massaged with a gloved fingertip for
3 min to enhance the penetration into HFs [54]. After 1 h incubation at 32 ◦C, the skin surface was
cleaned by means of tape stripping (Scheme 1a) [45,53].
For sufficient skin surface cleaning, 10 subsequent tape strips were pressed onto the skin surface
by using a paint roller to minimize the influence of furrows and wrinkles [45,55]. Afterwards,
the 1 mm diameter punch biopsies (equals 0.785 mm2) of follicular and interfollicular skin were
collected as described in Scheme 1b. Briefly, the surface-cleaned area of investigation was equally
divided into two parts. On one part, all HFs—described in Scheme 1b follicular skin, dark blue
punches—were collected by means of a stereomicroscope (Model SZX7, SZX2-ILLTQ, Olympus
Corporation, Tokyo, Japan). On the other part, the interfollicular skin—described in Scheme 1b
interfollicular skin, orange punches—were collected. Notably, an equal number of punch biopsies
were collected in each part and stored in 2 mL tubes. Moreover, a skin area of 4.91 cm2 including
the rest of the treated area and the surrounding skin was also punched (called “skin rest”) for TFB
mass balance calculation purposes [45]. Furthermore, TFB left on the materials that were in contact
with the formulation, including glove-fingertip, tape strips, and skin rest, were extracted in 2 mL of a
mixed MeOH:ammonium acetate buffer (pH 5.0, 5 mM) ratio of 60:40 v/v (called “extraction media”).
The 0.785 mm2 punch biopsies were extracted in 500 µL extraction media. All samples were sonicated
in an ultrasonic bath (Sonorex, Bandelin electronic GmbH and Co. KG, Berlin, Germany) for 1 h,
subsequent shaking at 350 rpm for 2 h. Following, the samples were centrifuged at 24.400 g, at 20 ◦C
for 5 min, the supernatant was filtered and if necessary diluted prior to LC-MS analysis (Supplemental
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part 3). According the FDA bioanalytical method validation guideline sensitivity criteria [56], the lower
limit of quantification (LLOQ) was at least 5 times higher than the response from the blank matrix
value. The LLOQ was determined separately for each different matrix type, by multiplying the highest
found blank matrix value times 5, and the values below LLOQ were excluded. The TFB mass balance
was determined for each treated area as follows:
Mass balance (%) = ((TFB in glove-fingertip + TFB in tape strips + TFB in follicular
and interfollicular skin punches + TFB in skin rest)/applied TFB amount on treated
area) × 100
(4)
Results are reported as mean ± SD, illustrated by a scatter dot plot.
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2.8.2. The Therapeutic Efficacy of TFB in an Allergic Dermatitis Mouse Model
In this study, we employed the allergic dermatitis mouse model to gain the first insights in the
therapeutic efficacy of the TFB SqD NPs. The efficacy of the TFB SqD NPs in reducing inflammatory
response was compared to the positive control—TFB-acet:DMSO—and aqTFB-C formulation (Table 2).
Drug-free SqD NPs and acetone:DMSO solution served as vehicle control groups. The reduction of
the ear swelling at 24 h post-challenging by allergen served as readout to evaluate the efficacy of a
formulation in reducing inflammatory response in mice.
Table 2. Abbreviation, composition, formulation type, and number of treated mice of treatment and
respective vehicle control groups for in vivo dermatitis mouse model study on biological response upon
topical application.
Group Abbreviation Components FormulationType No. Mice
Treatment
TFB 2 mg/mL
TFB SqD NPs TFB 1, SqD 2, phos-buffer 3 suspension 7
aqTFB-C TFB-C 4, phos-buffer 3 solution 7
TFB-acet:DMSO TFB 1, acetone:DMSO 5 (7:1 v/v) solution 7
vehicle control
Drug-free SqD NPs SqD 2, phos-buffer 3 suspension 7
Drug-free
acet:DMSO acetone:DMSO
5 (7:1 v/v) solution 7
1 tofacitinib free base, 2 anionic squalenyl derivative, 3 phosphate buffer, 4 tofacitinib citrate, 5 dimethyl sulfoxide.
The animal procedure was as follows: prior to the experiments, the allergic dermatitis mouse
model was established by sensitizing and challenging the mice for one month with the contact
allergen toluene 2,4 diisocyanate (TDI) in acetone as described in previous studies [47,57,58]. On the
experiment day, the ear thickness was measured and the formulations were applied (Scheme 2, −0.5 h).
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After 30 min, the mice were challenged by applying 20 µL and 30 µL of 0.5% TDI in acetone on the
mouse ear and the neck’s dorsal region, respectively (Scheme 2, 0 h). After 4 h, the formulations
were applied for the second time (Scheme 2, 4 h). The ear thickness was measured again at 24 h
post-challenge, and the mice were sacrificed afterwards (Scheme 2, 24 h). The reduction of the ear
swelling was determined by subtracting the ear thickness after 24 h of challenge from the ear thickness
before the challenge. Results are reported as mean ± standard error (SEM).
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inflammatory response was monitored by ear swelling reduction 24 h post-allergen challenge (TDI:
toluene 2,4 diisocyanate).
2.9. Statistics
Statistical a alysis was performed by Grap Pad Prism 8.0 or Microsoft Excel 2016/2019.
Significant differences b tween formulations in the ex vivo pig ear experi ent were tested for follicular
and interfollicular skin area separately by one-way ANOVA with multiple comparisons by Tukey’s test.
Significant difference between the vehicle control group and treatment group in in vivo mouse model
was detected by an unpaired two-tailed t-test. Significance levels are reported as follows: p ≥ 0.05: n.s.,
p = 0.01 to 0.05: *, p = 0.001 to 0.01: **, and p < 0.001: ***.
3. Results and Discussion
3.1. Characteristics of TFB SqD NPs
The stable and uniform TFB SqD NPs with a size of 239.1 ± 43.5 nm and PdI f 0.21 ± 0.01 (Table 3
and Figure S1) were formed by simultaneous self-assembly of the amphiphilic SqD and TFB using the
solvent evaporation method. The anionic SqD (Figure 1) containing a hydrophilic hydrogen sulfate
head-group and a hydrophobic squalenyl oiety potentially allows the loading of TFB (Figure 1) in
both compartments via charged and hydrophobic inte actions, respectively.
Table 3. Physicochemical characteristics, including size, polydispersity index (PdI), zeta-potential, pH,
loading capacity (LC) and encapsulation efficiency (EE), of SqD nanoparticles (NPs) determined by
dynamic light scattering (DLS), electrophoretic light scattering (ELS), pH measurements, and HPLC.




NPs TFB SqD NPs
size (nm) 225.7 ± 20.3 239.1 ± 43.5
PdI 0.19 ± 0.02 0.21 ± 0.01
zeta-potential (mV) −54.5 ± 1.7 −59.9 ± 2.3
pH 6.28 ± 0.02 6.31 ± 0.02
LC (%) N.A. 20.1 ± 2.1
EE (%) N.A. 19.8 ± 3.6
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We have previously reported the significant drug LC of SqD NPs yet also pointed
out that the loading of small molecules—containing polar groups and having rather poor
water-solubility—is challenging, only allowing e.g., the maximum LC at around 10% of a quorum
sensing inhibitor [43] or at around 9% of Nile red [44]. In this study, it is surprising that the LC of TFB
could be maximized at 20.1% ± 2.2%, with a corresponding EE at 19.8% ± 3.6%. Most importantly,
such a high LC of TFB in SqD NPs enhanced the TFB solubility in phos-buffer up to 2 mg TFB/mL,
which was around 40 times higher than the maximum solubility of TFB alone in the same buffer
(47.9 ± 0.2 µg/mL). The negative zeta-potential of the drug-free SqD NPs (−54.5 ± 1.7 mV, Table 3) did
not change upon drug loading (−59.9 ± 2.3 mV, Table 3), which led to the assumption that TFB might be
loaded rather via hydrophobic than charged interactions into SqD NPs [44]. It is worth noting that the
pH value plays a crucial role in the optimization of TFB loading. As the pH of human skin is slightly
acidic around 5 [59], a comparable pH of the formulation is hence preferred. However, the better
solubility of TFB in acidic pH [60] does not benefit the NP encapsulation. In our optimization, an ideal
compromise was found by preparing the TFB SqD NPs in a phos-buffer, resulting in a suspension with
a pH of 6.3 (Table 3).
The low negative zeta potential of the NPs (−59.9 ± 2.3 mV, Table 3) could stabilize the suspension
well by strong charge repulsion [61]. The drug-free SqD NPs having similar characteristics to the
TFB SqD NPs—a hydrodynamic size of 225.7 ± 20.3 nm, PdI of 0.19 ± 0.02, and zeta-potential of
−54.5 ± 1.7 mV—served as a control (Table 3 and Figure S2). The morphology of the NP-suspensions
was visualized by cryo-TEM, demonstrating homogeneous, dense, and spherical shaped NPs in both
drug-free SqD NPs (Figure 1a) and TFB SqD NPs (Figure 1b).
3.2. Stability of TFB SqD NPs
Both drug-free SqD NPs and TFB SqD NPs exhibited good colloidal stability at storage conditions
over 24 days (Figure 2a–c). Interestingly, the aqTFB-C solution (2 mg TFB/mL) in phos-buffer, showed a
lower pH value at 4.54 ± 0.03 compared to the NP formulations and was further decreasing to
4.17 ± 0.22 after 24 days at 4 ◦C (Figure 2d). This can be explained by the interaction of the citrate
salt with the disodium hydrogen phosphate, which forms a new buffer system and lowers pH [62].
Notably, crystals were visible in the TFB-C in phos-buffer solution upon storage at 4 ◦C after 2 weeks.
No visual changes were observed over the 24-days in drug-free SqD NPs and TFB SqD NPs.Pharmaceutics 2020, 12, x FOR PEER REVIEW 10 of 17 
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3.3. Release Profile of TFB SqD NPs
We evaluated the in vitro release profile of TFB SqD NPs and accessed the TFB stability in skin
mimicking conditions using HPLC [48,59]. Figure 3 shows a burst TFB release of around 40% in the
first 0.25 h followed by a continuous slower release of TFB until complete. This data set proves the
releasing capacity of the TFB SqD NPs. Moreover, the HPLC analysis of TFB over 24 h did not show
any signs of drug degradation. It is also important to highlight that a simple correlation between
in vitro and in vivo release of TFB SqD NPs cannot be drawn, since the lipid derived SqD NPs would
interact differently with the sebum milieu inside the HFs. In addition, the changing pH profile inside
HFs was not taken into account [63,64]. Therefore, further in vivo experiments would be necessary to
evaluate the release profile of TFB SqD NPs in HFs.
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3.4. Ex vivo and In vivo Performance of TFB SqD NPs
3.4.1. Targeted Follicular Transport of TFB in a Pig Ear Model
We first investigated the targeted follicular delivery of TFB in a pig ear model. The quantity of TFB
in nanograms per 0.785 mm2 follicular (Figure 4a) and interfollicular (Figure 4b) skin surface cleaned
punch biopsy was analyzed. The results were used to compare the performance of TFB SqD NPs
to TFB alone formulations—aqTFB-C, TFB-EtOH, and TFB-acet:DMSO. Moreover, TFB-acet:DMSO
has shown a significant effect in an allergic dermatitis mouse model compared to vehicle control [47].
Therefore, it was used as a standard to compare the performance of TFB SqD NPs.
Overall, the results clearly demonstrated that the follicular transport was the major route
for drug penetration compared to the interfollicular route. Figure 4a compares the TFB amount
in the follicular skin delivered by different formulations. The aqTFB-C and TFB-EtOH delivered
16.03 ± 5.11 ng/0.785 mm2 and 14.68 ± 5.59 ng/0.785 mm2 of TFB, respectively, into the follicular skin,
which were significantly less than that of the TFB SqD NPs at 30.06 ± 8.32 ng/0.785 mm2. Interestingly,
the ability of SqD NPs to deliver TFB to the follicular skin was found to be as good as the TFB-acet:DMSO,
which allowed the TFB delivery of 27.03 ± 5.60 ng/0.785 mm2.
As shown in Figure 4b, the TFB amount in interfollicular skin was, in contrast,
relatively low and not significantly different regardless of different tested formulations.
The amount of TFB penetrating interfollicular skin was slightly more pronounced when
using the TFB-acet:DMSO (5.14 ± 4.29 ng/0.785 mm2, Figure 4b) compared to the other tested
formulations (3.28 ± 1.91 ng/0.785 mm2 for TFB SqD NPs, 0.77 ± 0.20 ng/0.785 mm2 for aqTFB-C,
and 1.70 ± 1.26 ng/0.785 mm2 for TFB-EtOH, Figure 4b). The overall higher drug penetration by
follicular skin compared to interfollicular skin stresses the impact HFs have on general drug penetration
into skin, and are in good agreement to previous findings [65].
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Figure 4. TFB deposition in nanograms per 0.785 mm2 skin punch of surface-cleaned application area
in (a) follicular skin and (b) interfollicular skin. Treatment groups are presented as TFB SqD NPs in blue
circles, aqTFB-C in dark red squares, TFB-acet:DMSO in purple upward triangles, and TFB-EtOH in
pink downward triangles respectively. Results presented as mean ± SD in a scatter dot plot. Significant
differences are presented as p ≥ 0.05: n.s., p = 0.01 to 0.05: *, and p = 0.001 to 0.01: **, tested for follicular
and interfollicular skin separately by one-way ANOVA with multiple comparisons by a Tukey’s test.
The guideline of the scientific committee on consumer safety recommends a mass balance in the
range of 100%± 15% [66], these criteria were met for all formulation types except for the TFB-acet:DMSO
(Table 4). In addition to the total organic solvent-based formulation of TFB-acet:DMSO, the lack of
mass recovery leads to the assumption of uncontrolled and fast rug penetration and permeation.
Taking together, these results imply the advantages of using aqueous SqD NPs for the targeted follicular
delivery of TFB.
Table 4. Mass balance of TFB applied on application area in ex vivo pig ear skin experiment. Results are
pre ented as mean ± SD.
Treatment Group Mass Balance (%)
TFB SqD NPs 90.4 ± 6.4
aqTFB-C 87.4 ± 1.9
TFB-acet:DMSO 69.7 ± 10.7
TFB-EtOH 95.7 ± 3.3
3.4.2. The Therapeutic Efficacy of TFB in an Allergic Dermatitis Mouse Model
The topical formulation of TFB in an organic mixture of acetone:DMSO (7:1 v/v) has previously
shown a reduction in inflammatory response in an allergic dermatitis mouse model at all tested TFB
concentrations that ranged from 0.1% to 0.5% (w/v) compared to vehicle controls [47]. These results
implied the therapeutic efficacy of TFB at preclinical levels, and validated the allergic dermatitis mouse
model [47]. This Th2 driven mouse model resembles major characteristics of acute atopic dermatitis
(AD) lesions in regard to cytokine pattern and prediction of effectiveness of, e.g., phosphodiesterase
4 inhibitors [67], JAK-inhibitors [47], and glucocorticoids [57], all therapeutic options used or in clinical
phase for treatment of human AD.
Therefore, we used this model and TFB-acet:DMSO as a positive treatment control to evaluate the
therapeutic efficacy of TFB SqD NPs and aqTFB-C. Notably, it should be taken into account that the
acetone:DMSO solution cannot be considered as a safe drug delivery system for topical application.
DMSO itself might alter the cellular processes and cause some unknown biological effects [68,69].
Pharmaceutics 2020, 12, 1131 12 of 17
However, DMSO containing formulations are often used for preclinical research due to good drug
solubility in DMSO and penetration enhancing effects [69]. As shown in Figure 5, mice treated with
TFB-acet:DMSO demonstrated a significant reduction of around 50% in ear swelling compared to that
from the drug-free acet:DMSO (50.80 ± 11.09 µm and 97.97 ± 14.05 µm ear swelling, respectively),
which is in agreement with Fukuyama et al. [47]. The TFB SqD NPs were able to reduce the ear swelling
by around 20% compared to drug-free SqD NPs (76.20 ± 5.54 µm and 94.34 ± 11.71 µm ear swelling,
respectively). The aqTFB-C did not show any reducing effect (112.5 ± 30.16 µm ear swelling).
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Figure 5. Ear swelling reduction in in vivo allergic dermatitis mouse model after 24 h allergen challenge.
Application of formulation 30 min prior and 4 h after ch llenging. Teste trea ment groups are:
aqTFB-C (filled dark red bar), TFB SqD NPs (filled dark blue bar), including control group drug-free
SqD NPs (striped dark blue bar), and TFB-acet:DMSO (filled purple bar), cluding control g oup
drug-free acet:DMSO (st iped purple bar). Results are presented as mean ± SEM. Sig ifi a t diffe ence
between vehicle control group and treatment group was tested by n unpaired two-ta led t-test.
Significance levels are reported as p ≥ 0.05: n.s. and p = 0.01 to 0.05: *.
In general, these results were actually well correlated to the ex vivo pig ear outcomes. Particularly,
the aqTFB-C provided a very low penetration and permeation in both follicular and interfollicular
skin ex vivo, also performed poorly in the allergic dermatitis mouse model in vivo. Despite resulting
a comparable TFB delivery in follicular skin in the pig ear model, TFB SqD NPs did not reduce the
inflammatory response as much as TFB-acet:DMSO did in the mouse model. Such results could be
explained by the higher TFB interfollicular penetration and permeation of TFB-acet:DMSO, and it has
to be taken into account, that not only the follicular skin, but the whole treated skin area (follicular and
interfollicular) was affected in the allergic dermatitis mice model. Furthermore, the low mass balance of
TFB-acet:DMSO in the pig ear model also suggested that this formulation had uncontrollable penetration
and permeation rates and depth into the skin, possibly leading to an overall higher delivered TFB
amount into the whole skin tissue. As also discussed in the previous study, the addition of DMSO as a
vehicle for NP-suspension is likely to enhance the interfollicular skin permeation, while the aqueous
NP-suspension only maximized the follicular deposition [70]. These results demonstrate quite plainly
that it is important to take ex vivo data of penetration and permeation pathways into account when
evaluating in vivo data of drug effects of topically applied formulations. Taking the shown follicular
targeting of the ex vivo pig ear model and the measurable anti-inflammatory effect of the in vivo mouse
model into consideration, our TFB SqD NP was clearly the best option for safe and efficient delivery of
TFB into the HF. The appropriate TFB concentration for a topical delivery and the overall biological
effects have to be further determined, to meet the needs for a safe and effective nanomedicine against
AA and other skin diseases.
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4. Conclusions
In this study, we successfully showed the preparation of TFB SqD NPs with a satisfying drug LC
of 20% and an enhanced drug solubility, up to 40 times in phos-buffer compared to the plain drug.
Moreover, we maximized the targeted delivery of TFB into the hair follicles, as demonstrated in an
ex vivo pig ear model. Thereby, NPs were able to provide controlled drug delivery to the target site,
which is expected to minimize adverse effects due to high drug amounts in the interfollicular area and
high systemic drug levels. While safe and well tolerated by avoiding any organic solvent, TFB SqD
NPs showed a pharmacological effect in an in vivo mouse dermatitis model. Taking the ex vivo and
in vivo results together, we have clearly demonstrated, that TFB SqD NPs are favorable to achieve
controlled and targeted delivery of TFB into HFs.
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